Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Recruiting · NCT05876065 · Interventional (participants receive a specific treatment) · Lead sponsor: Wenjin Yin
View the official record on ClinicalTrials.gov →Interventions studied
TPCXC
What this trial is about
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Female, age≥18 years old
- ECOG≤2
- Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
- HR+/HER2+ or HR-/HER2+ or HR-/HER2-
- At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- Disease control (complete response + partial response + stable disease) after salvage treatment
- Expected survival ≥6 months
- Adequate organ function
Exclusion criteria
- during pregnancy and lactation
- Patients with central nervous system metastasis
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiaotong University - Shanghai, China